Advertisement

Topics

Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D

08:05 EDT 23 Sep 2016 | SCRIP

Cancer focused and charging forwards, AbbVie makes 2017 the year its pipeline will expand a little more. Scrip looks at...

      

Related Stories

 

Original Article: Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D

NEXT ARTICLE

More From BioPortfolio on "Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...